Welcome to the latest edition of our weekly EuroBiotech Report. While no politicians are rushing to Shire’s rescue as it attempts to fend off AbbVie, lawmakers in the United Kingdom are readying their strategies for the next time they do decide to intervene.
A fresh bid from Pfizer for AstraZeneca would spur them into action. And the government is confident it has the power to make it “dangerous” for Pfizer to go back on any promises. Having rebuffed Pfizer for now, AstraZeneca continues to build its R&D capabilities, with a deal between its virtual unit and the Max Planck Institute the latest step in its strategy.
As the likes of AstraZeneca have moved away from big in-house campuses and towards a more externalised R&D model, sites like Sandwich and Alderley Park have come onto the market. The success of these and other science parks is central to Britain’s R&D strategy, but some fear that the property developers that have been snapping up campuses are more interested in cost-cutting than innovation.
This article has been extracted from http://www.fiercebiotech.com, please click on this link to read the article in full http://www.fiercebiotech.com/story/uk-pols-ready-pfizers-return-az-cozies-eu-academia-israeli-biotech-upsizes/2014-07-10
Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:
ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.
With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.